Clinical Trial

Endothelial Dysfunction for Prognosis In Patients With preeClampSia

Study acronym: EPICS
Recruiting
View on ClinicalTrials.gov →
Summary
Preeclampsia is a pregnancy-specific hypertensive disorder and can progress rapidly to severe adverse outcomes affecting both the mother and the fetus. Endothelial and microcirculatory dysfunction mediate systemic preeclampsia-related organ dysfunctions. Changes in endothelial and vascular function in preeclampsia have been demonstrated through reduced flow-mediated vasodilation as a result of reduced availability of nitric oxide, which potentially persists up to several years postpartum. Hyperspectral imaging is a new innovative technology that allows to assess the peripheral microcirculation and perfusion non-invasively and contactless, but has never been evaluated in the context of preeclampsia before. This EPICS project (Endothelial dysfunction for Prognosis In patients with preeClampSia) is a prospective observational study and aims to investigate hyperspectral imaging as a new potential diagnostic and prognostic marker in preeclampsia.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-03-31; most recent amendment 2025-05-08.
Status change: Not Yet Recruiting → Recruiting 2025-05-08
Trial Details
NCT Number NCT06912477
Lead Sponsor Heidelberg University
Conditions Preeclampsia (PE), Hypertensive Disorder of Pregnancy
Enrollment 385 participants
Start Date 2025-05-08
Primary Completion 2026-12 (estimated)
Study Completion 2027-07 (estimated)
Updated on ClinicalTrials.gov 2025-05-11